### Curriculum Vitae

### Cecilia C. LOW WANG, MD, FACP

### **Current Positions**

2019-present *Professor of Medicine*, Division of Endocrinology, Metabolism & Diabetes,

Department of Medicine, University of Colorado School of Medicine, Aurora, CO

2014-present Director, Glucose Management Team, University of Colorado Hospital, Aurora, CO

2018-present Clinician-Scientist, CPC Clinical Research

2019-present Director, University of Colorado Diabetes Fellowship Program, Aurora, CO

### **Work Address**

University of Colorado School of Medicine

Anschutz Medical Campus
Department of Medicine

Division of Endocrinology, Metabolism, Diabetes

MS8106, RC-1 South 7103 12801 East 17<sup>th</sup> Avenue

Aurora, CO 80045

(Office) 303.724.7801 (Fax) 303.724.3920

(Pager) 303.266.0482

e-mail: Cecilia.LowWang@CUAnschutz.edu

### **Alternate Work Address**

**CPC Clinical Research** 

2040 N Scranton Street, Suite 2040

Aurora, CO 80045 Phone 303.860.9900 Fax 303.806.1288

e-mail: <u>Cecilia.LowWang@CPCMed.org</u>

### **Personal Data**

Place of Birth: Texas

Citizenship: United States of America

Former Names: Cecilia C. L. Wang, Cecilia C. Low

Languages: English (native speaker), Mandarin Chinese (spoken and written language proficiency)

### **Education**

| 1982-1984 | W. T. Woodson High School, Fairfax, VA   |
|-----------|--|
| 1984-1987 | Diploma, Taiwan Provincial Tainan Girls' Senior High School, Tainan, Taiwan            |
| 1987-1991 | Bachelor of Arts with Distinction in Chemistry. Senior Thesis passed with Distinction. |
|           | Pomona College, Claremont, CA  |
| 1991-1996 | Doctor of Medicine with Distinction in Research. University of Rochester School of     |
|           | Medicine, Rochester, NY  |

### **Postgraduate Training**

| 1996-1999 Intern and Resident, Department of Internal Medicine, University of Utah Hea     | .111      |
|--|-----------|
| Sciences Center, Salt Lake City, UT  |           |
| 1999-2000 Chief Resident in Internal Medicine, Department of Internal Medicine, University | ity of    |
| Utah Health Sciences Center, Salt Lake City, UT  |           |
| 2000-2003 Endocrinology Fellow, Division of Endocrinology, Metabolism & Diabetes, D        | epartment |
| of Medicine, University of Colorado Health Sciences Center, Denver, CO                     |           |

|          |                           | • 4        |
|----------|---------------------------|------------|
| Academic | Δn                        | pointments |
| Madeinic | $I \mathbf{X} \mathbf{D}$ | pomiuments |

| 2003-2004    | Instructor of Medicine, Division of Endocrinology, Metabolism & Diabetes, Department  |
|--------------|---|
|              | of Medicine, University of Colorado Health Sciences Center, Denver, CO                |
| 2004-2012    | Assistant Professor of Medicine, Division of Endocrinology, Metabolism & Diabetes,    |
|              | Department of Medicine, University of Colorado School of Medicine, Aurora, CO         |
| 2004-2019    | Director, Housestaff and Student Education, Division of Endocrinology, Metabolism and |
|              | Diabetes, Department of Medicine, University of Colorado School of Medicine, Aurora,  |
|              | CO  |
| 2006-present | Faculty, Medical Education Resources, Littleton, CO                                   |
| 2008-2018    | Associate Director of Fellowship/Education Programs, Division of Endocrinology,       |
|              | Metabolism and Diabetes, Department of Medicine, University of Colorado               |
|              | School of Medicine, Aurora, CO  |
| 2012-2019    | Associate Professor of Medicine, Division of Endocrinology, Metabolism & Diabetes,    |
|              | Department of Medicine, University of Colorado School of Medicine, Aurora, CO         |
| 2019-present | Professor of Medicine, Division of Endocrinology, Metabolism & Diabetes, Department   |
|              | of Medicine, University of Colorado School of Medicine, Aurora, CO                    |

### **Hospital Appointments**

| 2003-2016    | Staff Physician, Denver Veterans Affairs Medical Center, Denver, CO                    |
|--------------|--|
| 2003-present | Physician (Internal Medicine, Endocrinology), University of Colorado Hospital, Aurora, |
|              | CO   |
| 2009; 2012-  | Physician, University of Colorado Hospital Glucose Management Team, Aurora, CO         |
| present      |  |
| 2014-present | Director, Glucose Management Team, University of Colorado Hospital, Aurora, CO         |
| 2016-2018    | Physician, Aspen Valley Hospital, Aspen, CO  |

### CPC Clinical Research, Aurora, CO

| 2013-present | Medical Safety Officer, Department of Scientific and Medical Affairs |
|--------------|--|
| 2016-present | Safety Lead, Department of Scientific and Medical Affairs            |
| 2018-present | Clinician-Scientist, Department of Scientific and Medical Affairs    |

### Government

| 2016-2020    | Voting Member, Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food |
|--------------|---|
|              | and Drug Administration, Silver Spring, MD                                      |
| 2021-present | Chair, Endocrinologic and Metabolic Drugs Advisory Committee, U.S. Food         |
|              | and Drug Administration, Silver Spring, MD                                      |

### **Research Roles**

| 1988      | Research Assistant, Protein chemistry, Department of Biochemistry, National Cheng |
|-----------|---|
|           | Kung University Medical College, Tainan, Taiwan                                   |
| 1988-1989 | Laboratory Assistant, Plant physiology, Department of Biology, Pomona College,    |
|           | Claremont, CA   |
| 1989      | Research Assistant, Medicinal organic chemistry, Department of Chemistry, Pomona  |
|           | College, Claremont, CA  |

| 1990         | Research Fellow, Immunology, National Institute of Allergy and Infectious Diseases,<br>National Institutes of Health, Bethesda, MD  |
|--------------|---|
| 1992 & 1993  | Graduate Student, Neuroimmunology and aging, Department of Neurobiology and Anatomy, University of Rochester School of Medicine, Rochester, NY  |
| 1994-1995    | Honors Medical Student Fellow, Diabetes and metabolism, Endocrine/Metabolism Unit, Department of Medicine, University of Rochester School of Medicine, Rochester, NY  |
| 2001-2012    | Please see completed research funding section below   |
| 2014-2017    | Medical Safety Officer: A phase II multicenter, randomized, double-blind, controlled, parallel group study to evaluate the walking time effect of long-term ticagrelor in comparison to long-term aspirin administration in ambulatory patients with peripheral artery disease undergoing endovascular revascularization – The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR. |
| 2015-2017    | Medical Safety Officer: A multicenter, randomized, single-blind study with an open-label extension option to further evaluate the safety and efficacy of cryopreserved human amniotic membrane for the treatment of chronic diabetic foot ulcers  |
| 2016-present | Medical Monitor: Clinical effectiveness of conventional versus X-treated apheresis platelets in patients with hypoproliferative thrombocytopenia  |
| 2016-2020    | Clinical trial physician for 24-hour helpline: An international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients   |
|              | with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures  |
| 2017-2020    | International Clinical Adjudication Committee member: An international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures   |
| 2017-present | Medical Safety Officer: A Multicenter, Prospective, Randomized, Open-Label Study with a Crossover Extension Option to Evaluate the Safety and Efficacy of X for the Treatment of Chronic Venous Leg Ulcers  |
| 2018-present | Lead Principal Investigator: Phase 1 open-label safety study of X to heal chronic diabetic foot ulcers  |
| 2020-present | Principal Investigator: Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot) Pilot Program to Improve Diabetes and Cardiovascular Risk in Rural Communities COMIRB #21-2620. NCT04807218.   |
| 2020-2022    | Clinical Endpoint Committee member: NAPc2-201 and NAPc2-301 Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN-COVID-19). NCT04655586.   |
| 2021-present | Site Principal Investigator: Time In Glucose Hospital Target (TIGHT) Pilot Randomized Controlled Trial. COMIRB #22-0004.  |
| 2021-present | Sub-investigator: Balanced and Empowered EaTing (BEET) in Diabetes Study.  COMIRB #: 20-2382. PI: Phoutdavone "Noy" Phimphasone-Brady, PhD  |
| 2021-present | Sub-investigator: Role of Complex Sphingolipids in Diabetic Neuropathy. COMIRB #19-3004. PI: Vera Fridman, MD.  |

2021-present Sub-investigator: Multi-Session Feasibility Study Evaluating the Safety Effectiveness of

the Dexcom Continuous Lactate Monitoring (CLM) System PTL 904630. PI: Inigo San

Millan.

2022-present Site Principal Investigator: Tight in Glucose Hospital Target (TIGHT) ICU Observational

Trial. COMIRB #22-0012.

2022-present Data Safety Monitoring Board member. PRECIDENTD (PREvention of CardIovascular

and DiabEtic kidNey disease in Type 2 Diabetes) PCORI multicenter pragmatic

comparative effectiveness trial. NCT05390892.

### Completed/Closed Investigator-Initiated Funded Research

Oct 2010-Sep 2012 Principal Investigator

Regulation of Egr-1 in Insulin Resistance

Extension, Career Development Award-2, Department of Veterans Affairs Office of Research and Development, Medical Research Service, Washington, D.C.

May 2010-Dec 2011 Co-Investigator

Adiponectin as an independent determinant of ethnic differences in insulin

resistance

Clinical Translational Research Center study support, CTRC 6149UCH National Institutes of Health National Center for Research Resources

1UL1RR025780

Oct 2007-Sep 2010 Principal Investigator

Regulation of Egr-1 in Insulin Resistance

Career Development Award-2, Department of Veterans Affairs Office of Research and Development, Medical Research Service, Washington, D.C.

Oct 2004-Sep 2007 Principal Investigator

Insulin Resistance and Vascular Disease

Research Career Development Award, Department of Veterans Affairs Office of

Research and Development, Medical Research Service, Washington, D.C.

Jul 2004-Jun 2006 Principal Investigator

Diabetes Trust Foundation Clinical Scholars in Diabetes Fellowship.

Jul 2002-Sep 2004 Principal Investigator

Mechanism of the Mitogenic Influence of Hyperinsulinemia

Associate Investigator Program, Medical Research Service, Veterans Health

Administration, Department of Veterans Affairs, Washington, D.C.

Jul 2001 – Jun 2002 Research Fellow

Endocrinology, NIH Training Program Grant 5T32DK007446-22, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Health

Sciences Center, Denver, CO.

### Completed/Closed Investigator-Initiated Research (no direct funding)

Sep 2015-2018 Sub-Investigator

Vitamin D and Type 2 Diabetes Study (D2d) ClinicalTrials.gov Identifier: NCT01942694

### **Clinical Trial roles (no direct funding)**

| 2007-2013 | Safety Monitor - FLARE study (NIH/NIDDK R01) – lipectomy effects on metabolism |
|-----------|--|
| 2012-2016 | Safety Monitor - Timing Hypothesis for Estrogen Therapy Study (NIH/NIDDK R01)  |

### Colorado Clinical Translational Science Institute Leadership Innovating in Team Science (LITeS)

2016-2017 Tenth cohort. Group project: Catalyzing an Innovation-Entrepreneurship Ecosystem: The Faculty Perspective. Supported by Colorado CTSA Grant UL1
TR002535 from NCATS/NIH. Presented April 7, 2017

### **Professional Training**

| 2014-2015 | Medical Safety Officer training, CPC Clinical Research                                  |
|-----------|---|
| 2016-2017 | Leadership Innovating in Team Science (LITeS). Colorado Clinical Translational          |
|           | Science Institute.  |
| 2018      | Introductory Training Program in Quality Improvement, Institute for Healthcare Quality, |
|           | Safety and Efficiency (IHQSE), University of Colorado Anschutz Medical Campus           |
| 2021      | CCTSI Leadership Innovating in Team Science (LITeS) CliftonStrengths Workshop:          |
|           | Got Talent? Fostering Great Strengths   |
| 2021      | University of Colorado 2020-2021 four-part Equity Certificate Program:                  |
|           | Unconscious Bias and Virtual Settings, From Bystander to Active Allyship,               |
|           | What's in a Name? Equity Concepts, Leading through an Equity Lens.                      |

### Relevant Coursework - University of Colorado Graduate School

CLSC 7500 - Practical Application of Molecular and Cell Biology Techniques for the Clinical Investigator (audited 3 credit hr)

CLSC 7400 – Theory and Application of Techniques for the Study of Human Metabolism *In Vivo* (3 credit hr)

CLSC 6550 - Applications of Biostatistics to Clinical Research Questions (1 credit hr)

### Certification

State of Colorado Department of Regulatory Agencies Division of Registrations Board of Medical Examiners License for Practice of Medicine: 038877; effective until April 2023

U.S. Drug Enforcement Administration Controlled Substance Registration Certificate: #BL5553056

Diplomate, National Board of Medical Examiners (U.S. Medical Licensing Examination) 1997

Diplomate in Internal Medicine. American Board of Internal Medicine 2000

Diplomate in Endocrinology, Diabetes and Metabolism. American Board of Internal Medicine 2002, recertified until 2022

Basic Life Support certification: effective until Feb 2015

Utah Department of Occupational and Professional Licensing

Physician and Surgeon: #97-342784-1205; expired Jan 2001 Controlled Substance: #97-342784-9915; expired Jan 2001

### **Awards and Honors**

1987 International Red Cross Award for Community Service, Taiwan Chapter

1990 Introduction to Biomedical Research Program, National Institute of Allergy and Infectious

- Diseases, National Institutes of Health, Bethesda, MD
- 1991 Stanley D. Wilson Prize in Chemistry, Pomona College, Claremont, CA
- 1995 Distinguished Research Award, Associated Medical Schools of New York, New York, NY
- 1996 Rochester Society of Internal Medicine Prize Award, Rochester Academy of Medicine, Rochester, NY
- 1996 Charles D. Kochakian Award in Endocrinology and Nutrition, University of Rochester School of Medicine, Rochester, NY
- 1997 Outstanding Internal Medicine Intern, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT
- 1998 National Institutes of Health National Medical Association Clinical Fellowship Travel Award, National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD
- 2001 Stanford University Osteoporosis Preceptorship, Stanford University School of Medicine, Stanford, CA
- 2002 Loan Repayment Program for Clinical Researchers, National Institutes of Health, Bethesda, MD
- 2002 Endocrine Fellows Forum and Travel Award, Endocrine Fellows Foundation and American Diabetes Association, Alexandria, VA (ADA)
- 2002 Pfizer Scholars in Endocrinology Award, Pfizer Inc., New York, NY
- 2003 Western Society for Clinical Investigation Travel Award, American Society for Clinical Investigation, Ann Arbor, MI
- 2003 *WAFMR/Aventis Scholar*, Western Regional Meeting, American Federation for Medical Research, Manchester, MA
- 2003 *AstraZeneca Scholarship*, 3<sup>rd</sup> International Workshop on Insulin Resistance, International Medical Press, Atlanta, GA
- 2004 Women in Endocrinology Abstract Award, Women in Endocrinology, Boston, MA
- 2004 NIH NIDDK K08 Mentored Clinical Scientist Development Award: priority score 151. Selected for funding but declined because of simultaneously-awarded other research funding
- 2004 Clinical Scholars in Diabetes Fellowship, Diabetes Trust Foundation, Birmingham, AL
- 2005 Aventis Metabolism Scholar Award, Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2008 State-of-the-Art Invited Lecture in Metabolism, Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2009 Fellowship of the American College of Physicians, American College of Physicians, Philadelphia, PA
- 2009 Phase I Award, Novel Clinical and Translational Methods Development Program, Colorado Clinical & Translational Sciences Institute, Aurora, CO
- 2012 Keynote speaker, Rocky Mountain Chinese Society for Science and Engineering Annual Meeting, Denver, CO
- 2014 *Symposium speaker*, Italian Society of Diabetology National Meeting, Bologna, Italy. Clinical Symposium entitled "Treatment of the diabetic patient in the hospital"
- 2016 Master Clinician presenter, Diabetes, Endocrine Society Annual Meeting 2016, Boston, MA
- 2016-2017 Leadership Innovating in Team Science (LITeS) Colorado Clinical Translational Science Institute Tenth cohort. Group project: *Catalyzing an Innovation-Entrepreneurship Ecosystem: The Faculty Perspective*. Presented April 7, 2017

### **Membership in Professional Organizations**

| Sigma Xi   |
|--|
| Associates Committee, American College of Physicians/American Board of Internal    |
| Medicine Utah Chapter  |
| American Federation for Medical Research   |
| Women in Endocrinology   |
| Committee Member, Basic Research Subcommittee, Research Affairs Committee,         |
| Endocrine Society  |
| Committee Member, Trainee Development Committee (formerly "Associates Council"),   |
| Endocrine Society  |
| Committee Member, Clinical Research Subcommittee, Research Affairs Committee,      |
| Endocrine Society  |
| American Heart Association   |
| Committee Member, Scientific and Educational Programs Core Committee, Endocrine    |
| Society  |
| Committee Member, Research Affairs Core Committee, Clinical Research Subcommittee, |
| Endocrine Society  |
| Task Force Member, Strategic Plan 4 Task Force, Endocrine Society                  |
| American College of Physicians   |
| Colorado Society for Endocrinology and Metabolism                                  |
| Endocrine Society  |
| American Diabetes Association  |
| American Association of Clinical Endocrinology                                     |
| Committee Member, Clinical Diabetes and Endocrinology Annual Conference Program    |
| Committee, Clinical Diabetes Endocrine Institute                                   |
| Fellow, American College of Physicians, Philadelphia, PA                           |
|  |

### **Committee and Service Responsibilities**

### **National**

| T 1 1    | <b>D</b> | 1         | . •  | a : 1    | $\sim$ . | 1 1    |
|----------|----------|-----------|------|----------|----------|--------|
| Hood and | I lorg A | dminiatra | tion | V1 17701 | Chrina   | N/II N |
| Food and | Diug A   | amminisua | นเบน | SHVCI    | SULINE.  |        |

| 2016-2020    | Voting Member, Endocrinologic and Metabolic Drugs Advisory Committee |
|--------------|--|
| 2021-present | <i>Chair</i> , Endocrinologic and Metabolic Drugs Advisory Committee |

| Endocrine Soc | iety, Washington, D.C.  |
|---------------|---|
| 2003-2004     | Committee Member, Basic Research Subcommittee, Research Affairs Committee,        |
| 2003-2007     | Committee Member, Trainee Development Committee (formerly "Associates Council"),  |
| 2004-2007     | Committee Member, Clinical Research Subcommittee, Research Affairs Committee,     |
| 2007-2010     | Committee Member, Scientific and Educational Programs Core Committee              |
| 2010-2013     | Committee Member, Research Affairs Core Committee, Clinical Research Subcommittee |
| 2014-2019     | Committee Member, Trainee & Career Development Core Committee                     |
| 2016-2017     | Member, Strategic Plan 4 Task Force   |
| 2019-present  | Committee Member, Clinical Endocrine Update Steering Committee                    |
| 2021-present  | Committee Member At-Large, Nominating Committee                                   |

### American Association of Clinical Endocrinology

| 2021-2022    | Chair, Diabetes Disease State Network                                      |
|--------------|--|
| 2021-2022    | Member, 2022 Annual Meeting Program Subcommittee                           |
| 2021-present | Member, Disease State Network Oversight Committee                          |
| 2021-present | Member, AACE Comprehensive Type 2 Diabetes Management Algorithm Task Force |
| 2022-present | Vice Chair, Disease State Network Oversight Committee                      |

### **American Heart Association**

2022-present *Member*, Lifestyle Diabetes Committee, Council on Lifestyle and Cardiometabolic Health

### American College of Diabetology

2022-present Founding Board Member

2022-present *Treasurer* 

### **School of Medicine**

### University of Colorado School of Medicine

| 2004-2006 | Member, Metabolism Block Subcommittee for development of 2nd year curriculum |
|-----------|--|
| 2012-2013 | Member, Advanced Studies (Phase IV) Committee                                |

### University of Utah School of Medicine

| 1996-2000 | Member, Housestaff/Faculty Committee                             |
|-----------|--|
| 1997-1999 | Member, Advisory Committee (for Promotion, Retention and Tenure) |
| 1999-2000 | Member, Cardiopulmonary Resuscitation Committee                  |

### **University**

### Colorado Multiple Institutional Review Board, University of Colorado Anschutz Medical Campus

2006-2007; Panel Member, Panel B. Ad hoc VA representative, Panel A

2010-2014

### Action for Health in Diabetes (Look AHEAD) trial of intensive lifestyle intervention in type 2 diabetes,

### Denver, CO site

2007-2013 Study Physician

### **Departmental/Division**

### Department of Medicine

| 2004-2016; | Interviewer, Intern Applicants |
|------------|--------------------------------|
|            |                                |

2020-present

| 2012-2013 | Member, Morbidity and Mortality Committee, Department of Medicine |
|-----------|---|
| 2015-2019 | Member, Physician Scientist Training Program Selection Committee  |

2017-present Interviewer, Intern Applicants for Medicine-Pediatrics Housestaff Training Program

### Division of Endocrinology, Metabolism, and Diabetes

2008-2011 Faculty Organizer, Grand Rounds for Division of Endocrinology, Diabetes and

Metabolism

2008-2018 Associate Program Director, Fellowship/Education

2008-2018 Director, Endocrine Elective Rotation
 2018-present Member, Clinical Leadership Committee

2020-present Founding Program Director, Diabetes Fellowship

### **Hospital**

### Denver VA Medical Center, Denver, CO

2008-2010 *Member*, Institutional Animal Care and Use Committee

### University of Colorado Hospital, Aurora, CO

2015 Member, Access Working Group

2015-2016 Member, JCAHO Inpatient Diabetes Certification Working Group

2016-present Member, Diabetes Advancement Committee

2022-present Co-Chair, Endocrine Collaborative Care Review Committee

2022-present *Member*, Endocrine Safety Committee

### University Physicians Incorporated, Aurora, CO

2016-2017 Member, Diabetes Outpatient Workgroup

### **Review and Referee Work**

### **Grants**

Endocrine Fellows Foundation Fellows Development Research Grant Program in Diabetes, Obesity and Fat Cell Biology (2011)

American Heart Association Lipids Clinical Committee Grants (2012)

Endocrine Fellows Foundation Marilyn Fishman Grant for Research in Obesity and Type 2 Diabetes (2013, 2014)

Endocrine Fellows Foundation EFF Endocrine Research Grant (2014, 2015, 2019)

### Awards/Funding

Endocrine Society Lilly Award Grant (2010)

Endocrine Society Early Investigator Award (2011, 2012, 2014, 2015, 2018, 2019, 2020)

Endocrine Society Summer Research Fellowship (2012)

Endocrine Society Clinical Research Fellowship Award in Women's Health (2013)

Endocrine Society Acromegaly Research Fellowship Award (2019)

### **Abstracts**

Western Regional Meeting – American Federation for Medical Research (2008, 2011)

Endocrine Society ENDO Scientific Sessions – Endocrine Society (2012, 2013, 2015, 2016, 2018)

Reducing Health Disparities in Type 2 Diabetes Mellitus Summit –Endocrine Society (2013)

*University of Colorado Education Innovation Symposium* (2015, 2018)

International Congress on Endocrinology/Endocrine Society 2014 16th International Congress of Endocrinology & Endocrine Society's 96th Annual Meeting & Expo (2014; also judged for the Presidential Poster Competition)

American Diabetes Association Scientific Sessions (2016)

### Journals (Ad Hoc)

American Journal of Hypertension, Arteriosclerosis, Thrombosis, and Vascular Biology, BMJ Open Diabetes Research & Care, Cardiovascular Diabetology, Circulation, Clinical Diabetes, Clinical Diabetes and Endocrinology, Clinical Pharmacology & Therapeutics, Diabetes, Diabetes Care, Diabetes Research and Clinical Practice, Diabetes Spectrum, Diabetologia, Endocrine, Endocrine Practice, European Journal of Endocrinology, Hospital Practice, Journal of Diabetes Science and Technology, Journal of Hospital Medicine, Journal of the American Heart Association, Lancet Diabetes and Endocrinology, PLOS One, Vascular Medicine

### **Editorial Board**

2019-present Online Resources: Specialty Editorial Board, Dynamed Plus. American College of Physicians Endocrinology Topic Reviewer: Clinical Overviews and Recommendations in Diabetes.

### Invited extramural lectures, presentations and visiting professorships

### **Local (29)**

- 2003 *Menopause workshop* for Christian Women's Life Changes Seminar, New Jerusalem Missionary Baptist Church, Fountain, CO
- 2005 Setting Goals. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2006 Workup for thyrotoxicosis. Salud Family Clinic, Longmont, CO
- 2006 Vascular calcification: intersection of bone and vascular biology. Endocrine Grand Rounds, University of Colorado School of Medicine Department of Medicine Division of Endocrinology, Metabolism and Diabetes, Aurora, CO
- 2006 New diabetes agents and their role in type 1 and type 2 diabetes. University of Colorado Department of Medicine Internal Medicine Update, Estes Park, CO
- 2006 *Making Sense of Your Cholesterol.* Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2007 *Insulin effects in vascular smooth muscle cells*. Endocrine and Hormonal Malignancies Research Conference, University of Colorado School of Medicine, Aurora, CO
- 2007 *The Slippery Slope of Lipid Profiles*. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO
- 2008 Managing hyperglycemia to reduce microvascular complications in type 2 diabetes (talk and panel discussion). Look AHEAD trial, Denver, CO
- 2008 Diabetic neuropathy. University of Colorado School of Medicine Endocrine Practice Monthly Diabetes Conference, Aurora, CO
- 2008 Vitamin D: insulin sensitivity and vascular disease. University of Colorado Cardiometabolic disease Across the Lifespan (CALM) monthly conference, Aurora, CO
- 2009 *Diabetic neuropathy the forgotten complication*. University of Colorado School of Medicine General Internal Medicine Practice Clinical Conference, Aurora, CO
- 2009 Lipids: Issues in Diabetes. Diabetes Fall and Spring Conferences, Eastern Colorado Health Care System Denver VA, Denver, CO

- 2009 *Diabetic neuropathy*. University of Colorado School of Medicine General Internal Medicine Garfield Clinic Conference, Denver, CO
- 2011 *Vitamin D and Cardiovascular Disease*. Presbyterian-St. Luke's Hospital Internal Medicine Grand Rounds, Denver, CO
- 2011 Vitamin D and Cardiovascular Health: Association or Causation? University of Colorado School of Medicine Division of Endocrinology Grand Rounds, Aurora, CO
- 2011 Molecular mechanisms of vascular dysfunction in a novel porcine model of diet-induced obesity. VA Research Days, Denver VA Medical Center, Denver, CO
- What a Difference 10 Years Makes! Advances in Diabetes Over the Last 10 Years (talk and panel discussion). Look AHEAD trial retention event, Denver, CO
- 2012 Update What's Hot in Diabetes (talk). Look AHEAD trial retention event, Denver, CO
- 2013 Eye Health and Retinopathy. Look AHEAD trial retention event, Denver, CO
- 2014 From Aspirin to Insulin. American Diabetes Association Expo, Denver, CO
- What you need to know about diabetes in 2014. Colorado Heart Healthy Solutions New Community Health Worker Workshop, Aurora, CO
- 2015 Diabetic Ketoacidosis: Innovative Strategies for a Challenging Condition. University of Colorado School of Medicine Division of Endocrinology Grand Rounds, Aurora, CO
- 2018 *Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome*. Lecture. Advanced Practice Providers, Medical Intensive Care Unit, University of Colorado Hospital, Aurora, CO
- 2020 *Diabetes 2020 Update for Colorado Heart Healthy Solutions*. Colorado Heart Healthy Solutions Community Health Navigator Training Workshop, Aurora, CO
- 2021 *CoViD-19, Hyperglycemia and Diabetes What's the Connection?* University of Colorado Endocrinology Division Grand Rounds Co-presenter, Aurora, CO.
- 2021 Inpatient Hyperglycemic Management Diabetes Technology in the Hospital. Lecture, University of Colorado Division of Hospital Medicine Grand Rounds. Co-presenter with Maria Klimenko, MD, and Stacey Seggelke, CNS, Aurora, CO.
- 2021 Continuous Glucose Monitoring in the Non-ICU Setting Journal Club. Lecture. University of Colorado Division of Hospital Medicine All-Site Journal Club.
- 2022 Hypoglycemia in Older Adults: What Should We Target for Glucose Control in Diabetes? Lecture. University of Colorado Division of Geriatric Medicine Grand Rounds.

### Regional (17)

- 2006 New diabetes agents and their role in type 1 and type 2 diabetes. University of Colorado Department of Medicine Internal Medicine Update, Estes Park, CO
- 2006 Treatment paradigms for diabetes. Fall 2006 Primary Care Conference of the Community Health Association of Mountain/Plains States and the Northwest Regional Primary Care Association, Denver, CO
- 2007 New horizons in diabetes treatment. American Academy of Nurse Practitioners Wyoming Fall Conference, Cheyenne, WY
- 2007 Nephropathy and end-stage renal disease in diabetes Management Issues. Grand Junction VA Medical Center educational sessions, Grand Junction, CO.
- 2007 *Making sense of insulin therapy for type 2 diabetes*. Grand Junction VA Medical Center educational sessions, Grand Junction, CO.
- 2008 Aortic insulin signaling is perturbed in a large animal model of diet-induced obesity. State-of-

- the-Art Invited Lecture in Metabolism: Western Tri-Societies meeting, American Federation for Medical Research, Manchester, MA
- 2008 Session Chair, Western Tri-Societies Meeting, American Federation Medical Research
- 2008 *Lipids in women* (talk and panel discussion). 6<sup>th</sup> Annual Colorado Women's Cardiovascular Health Symposium. Center for Women's Health Research, Denver, CO
- 2012 *Diabetes It's not just about the sugar!* Rocky Mountain Chinese Society of Science and Engineering 30<sup>th</sup> Annual Conference, Denver, CO
- 2013 Diabetes and Cardiovascular Disease: Current Data and How to Prioritize Risk Reduction (talk and panel discussion). 11<sup>th</sup> Annual Colorado Women's Cardiovascular Health Symposium. Center for Women's Health Research, Aurora, CO
- Where and How Does Vitamin D Fit into Women's Health Care? Colorado Obstetrics and Gynecology Society annual meeting, Denver, CO
- 2014 *Diabetes and Cardiovascular Risk.* 30<sup>th</sup> Annual Winter CME Meeting, Colorado Academy of Physicians Assistants, Copper Mountain, CO.
- 2015 Advanced Insulin Management and Delivery. American Diabetes Association 3rd Annual Advanced Diabetes Practice for Primary Care conference, Denver, CO
- 2015 *Type 2 Diabetes*. Family Medicine Forum, Florida Academy of Family Physicians, Palm Beach, FL
- 2015 Obesity. Family Medicine Forum, Florida Academy of Family Physicians, Palm Beach, FL
- 2016 *Insulin Therapy for Type 2 Diabetes: When and How.* Rocky Mountain Metabolic Syndrome Symposium 2016, Aurora, CO
- 2020 Diabetes: Putting it all together to design a high value diabetes regimen for your patient. American College of Physicians Colorado Chapter Meeting, Colorado Springs, CO.

### National (38)

- 2003 Visiting Professor, University of Utah Health Sciences Center, Salt Lake City, UT Insulin and vascular smooth muscle cell phenotype. Research Seminar, Cardiac and Vascular Biology Group Thyroid emergencies. Internal Medicine Housestaff noon conference
- 2005 Co-moderator for Clinical Investigator's Workshop for Trainees, Endocrine Society
- 2010 Early defects occur in PI3-kinase/Akt signaling and vascular function in a novel porcine model of diet-induced obesity. American Diabetes Association Scientific Sessions, Orlando, FL
- 2012 Symposium chair: CVD Risk in Diabetes Is Glucose Important? *ENDO 2012*, Houston, TX. Endocrine Society.
- 2012 Session Chair, Clinical Research Fellowship and Mentor Oral Presentation session, ENDO 2012, Houston, TX. Endocrine Society.
- 2014 Inpatient Hyperglycemia in Select Populations. Clinical Diabetes and Endocrinology in 2014 Conference, Snowmass, CO
- 2014 Symposium chair: Diabetes: An Assault on the Vasculature. *16th International Congress of Endocrinology & the Endocrine Society's 96th Annual Meeting & Expo*, Chicago, IL. Endocrine Society.
- 2015 Co-chair, 2015 Oral Presentations in Reproductive Science Competition, Endocrine Society Annual Meeting 2015
- 2016 Management of Hyperglycemia in the Inpatient Setting. Endocrine Society Annual Meeting Meet

- the Professor Sessions, Boston, MA
- 2017 New Insulin Therapies Practice Changing? Clinical Diabetes and Endocrinology 2017 Snowmass, CO.
- 2017 Chair, Symposium: *Can We Improve Cardiovascular Risk in Type 2 Diabetes?* Endocrine Society Annual Meeting 2017
- 2017 Moderator, panel discussion of cases: *Mixed-up Metabolism Obesity and Lipid Disorders*. Clinical Diabetes and Endocrinology 2017 Snowmass, CO.
- 2017 Insulin Management Algorithms for the Inpatient Setting. Symposium. American Diabetes Association 77<sup>th</sup> Scientific Sessions, San Diego, CA
- 2017 Recurrent DKA An Approach to a Recurrent Challenge. Association of Diabetes Centers: PRIDE and PROUD Meeting, American Diabetes Association 77th Scientific Sessions, San Diego, CA
- 2018 A Balancing Act: Benefits vs Risks of Diabetes Therapies. Clinical Diabetes and Endocrinology 2018 Snowmass, CO
- 2018 Complications and Comorbidities: Challenging Diabetes Cases. Case developer and Moderator, panel discussion of cases: Clinical Diabetes and Endocrinology 2018 Snowmass, CO
- 2018 Effective Inpatient Glucose Management Team Structure and Function. Planning Research in Inpatient Diabetes (PRIDE) General Session, American Diabetes Association 78<sup>th</sup> Annual Scientific Sessions, Orlando, FL.
- 2019 Which Treatments for Diabetes? Getting to the "Heart" of the Matter. 20th Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2019 Workshop 3: Diabetes and Cardiovascular Disease. 20th Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2019 Diabetes Case Presentations Panel Discussion. Panelist. 20<sup>th</sup> Annual Diabetes Conference: Current Treatments for Diabetes Complications. University of Rochester School of Medicine and Dentistry, Rochester, NY.
- 2019 *Dilemmas in Diabetes Management Case-Based Panel Discussion*. Panelist, Colorado Diabetes and Endocrinology Institute 55<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2019 Diabetes and Lipid-Lowering Which Treatment for Which Patient? Panelist, In session 763.
  Ambulation to Rivaroxaban: Branching outside the coronaries. American College of Cardiology ACC.19 Scientific Sessions 2019, New Orleans, LA.
- 2019 Co-Chair, Oral abstract session *OR 28. Metabolism, Diabetes and Obesity: New Mechanisms and Models.* ENDO 2019 Endocrine Society 101<sup>st</sup> Annual Meeting and Expo, New Orleans, LA.
- 2019 Cardiovascular and Limb Outcomes in Patients with DM and Peripheral Artery Disease. 3<sup>rd</sup> Annual Heart in Diabetes. Philadelphia, PA.
- 2020 Panelist, *Challenges in Diabetes Case-Based Panel Discussion*. Colorado Diabetes and Endocrinology Institute 56<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2020 Which Therapy for Which Patient? Complexities in Diabetes Management. Clinical Diabetes and Endocrinology Institute 56<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2020 Managing Risk in Survivors on Androgen Deprivation. American College of Cardiology ACC.20 Virtual Annual Meeting, Chicago, IL.
- 2020 Management of Steroid Associated Hyperglycemia in Inpatient and Outpatient Settings.

- Professional Interest Group Discussion on Clinical Centers & Programs Frequently Encountered Glycemic Management Issues Without Clear Guidelines. American Diabetes Association 80<sup>th</sup> Scientific Sessions, Virtual Meeting.
- 2020 Severe Hypoglycemia: The Frequently Forgotten Threat. Endocrine Society ENDO 2020 Online Meeting. CME MOC Special Program.
- 2020 Whose Job Is It? Multidisciplinary Management of Peripheral Artery Disease. Moderator. Educational panel discussion webinar presented during American Diabetes Association Scientific Sessions (Virtual).
- 2020 Lowering Glucose in Older Patients: How Much is Too Much? Session #: GR.CVS.446, Session Title: Cardiovascular Disease Prevention in Older Adults: Reconciling Recommendations with Reality. American Heart Association 2020 Scientific Sessions (Virtual).
- 2021 How Will This Impact FDA Approval of Diabetes Drugs? In Symposium S20: More Than A1c: Important Outcomes for Those With Diabetes. Endocrine Society ENDO 2021 Annual Meeting (Virtual).
- 2021 Diabetes Technology in the hospital and peri-operative period. Meet the Expert session. American Association of Clinical Endocrinology. Envision: AACE Annual Meeting 2021. (Virtual)
- 2021 Leaping Into the Future: Novel Therapies for Peripheral Artery Disease. Content developer and Panelist. Society for Vascular Medicine Annual Meeting 2021. On-Demand Webinar.
- 2022 *Obesity Management in 2021: Obesity Panel.* Panelist. Clinical Diabetes and Endocrinology Institute 57<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2022 *Individualized Treatment for Diabetes (Type 2): Diabetes Panel.* Panelist. Clinical Diabetes and Endocrinology Institute 57<sup>th</sup> Annual CME Conference, Snowmass, CO.
- 2022 Disease State Network Year in Review: Diabetes. American Association of Clinical Endocrinology Annual Meeting 2022, San Diego, CA.
- 2022 Successful Co-Management Between Endocrinology and Primary Care Diabetes. American Association of Clinical Endocrinology Annual Meeting 2022, San Diego, CA.

### **International (3)**

- 2014 Anti-hyperglycemic therapy in the patient on enteral nutrition. Symposium speaker, Italian Society of Diabetology National Meeting, Bologna, Italy.
- 2020 *CoViD-19 and Diabetes: What Have We Learned So Far?* Symposium speaker, National Physicians Association of Zimbabwe NAPAZ Annual Sessions (Virtual).
- 2020 Best Medical Therapy to Support Successful Revascularization. Organizer and panelist, European Society for Vascular Surgery (Virtual).
- Walking Into the Future Multifaceted Care to Reduce Vascular Risk in Diabetes. Content developer and moderator. European Association for the Study of Diabetes Annual Meeting 2021. Symposium. (Virtual)

### **TEACHING RECORD**

Teaching Portfolio available upon request, containing additional details of educational activities including course development, syllabi, and teaching evaluations

### **High School Students**

### **CU Pre-Health Scholars Program (CUPS)**

Health Disparities in Diabetes. Summer course: Health, Equity and Social Justice. University of Colorado Anschutz Medical Campus, Aurora, CO.

### **Undergraduate Students**

### Dine College, Tsaile, AZ

2010 Medicine as a career path. Clinical Translational Science Award (CTSA) Education and Training Pillar, Aurora, CO Summer Research Enhancement Program in Cancer and Diabetes Prevention. University of Colorado School of Medicine

2010 NIH Clinical Translational Science Award Education and Training Pillar, University of Colorado School of Medicine Aurora, CO. Research presentation advisor for Summer Research Enhancement Program in Cancer and Diabetes Prevention

### **Graduate and Medical School Students**

### Summer Research Fellowship Webinar, Endocrine Society

2016, 2017, 2018, 2019 How to Choose a Good Mentor and Be a Good Mentee.

### **Graduate School Students**

### **University of Colorado Health Sciences Center Graduate School**

2006 RPSC 7801: Endocrinology and Metabolism. *Thyroid function and disease* (1 hr).
 2009 Reproductive Sciences Graduate Program: "*Insulin resistance and diabetes mellitus: Clinical correlates*" (1 hr), University of Colorado School of Medicine, Aurora, CO

### **Medical School Students**

### **University of Utah School of Medicine**

Morning report 4 days/week, Morbidity and Mortality Conferences 2/month, 3<sup>rd</sup> and 4<sup>th</sup> year medical student EKG sessions weekly, medical service attending 7.5 weeks.

Organized departmental Grand Rounds and daily housestaff and medical student noon conferences

### **University of Colorado School of Medicine**

| chirtistey or c | 50101 and School of Medicine  |
|-----------------|---|
| 2002-2006       | Gastrointestinal, Endocrine and Metabolism Block small group facilitator (2 <sup>nd</sup> -year     |
|                 | medical students): 12-14 hr/yr  |
| 2003-2011       | Ward attending for Medical Service, 2-4 weeks/yr, Denver VA Medical Center                          |
| 2003-2015       | Consult attending for Endocrine Inpatient Consult Service, 2-6 weeks/yr, University of              |
|                 | Colorado Hospital and Denver VA Medical Center  |
| 2004-2007       | Foundations of Doctoring small group facilitator: abdominal, head and neck, and                     |
|                 | pulmonary exams, cardiovascular risk assessment, and Transition to Third Year oral                  |
|                 | presentations (2 <sup>nd</sup> -year medical students)  |
| 2006            | Lecturer, Gastrointestinal, Endocrine and Metabolism Block (2 <sup>nd</sup> year medical students): |
|                 | Non-insulin glucose-lowering therapies for diabetes (1 hr/yr)                                       |
| 2006-2017       | Digestive, Endocrine and Metabolism Block small group facilitator (2 <sup>nd</sup> year medical     |
|                 | students): 4-8 hr/yr  |
| 2007-2010       | Life Cycle Block male and female reproductive small group discussions (2 <sup>nd</sup> year medical |

|              | students): 2-4 hr/yr  |
|--------------|---|
| 2007-2021    | Lecturer, Digestive, Endocrine and Metabolism Block (2 <sup>nd</sup> yr medical students): <i>Non-</i>    |
|              | insulin therapies for diabetes (1 hr/yr)  |
| 2007-2021    | Lecturer, Digestive, Endocrine and Metabolism Block (2 <sup>nd</sup> yr medical students): <i>Insulin</i> |
|              | therapy for diabetes (1 hr/yr)  |
| 2008         | Adult Ambulatory Care Clerkship Chronic Disease Experience Subspecialty Preceptor                         |
|              | for 3 <sup>rd</sup> yr medical students   |
| 2008         | Lecturer, Digestive, Endocrine and Metabolism Block (2 <sup>nd</sup> yr medical students):                |
|              | Pathophysiology of type 2 diabetes (1 hr)   |
| 2006         | Lecturer, PATH 8001: Interpretive Clinical Pathology (4 <sup>th</sup> year medical students).             |
|              | Reproductive endocrinology laboratory testing (2 hr).   |
| 2010         | Poster judge for Mentored Scholarly Activity Capstone Event (4 <sup>th</sup> yr medical students)         |
| 2012-2015,   | Ward attending for Internal Medicine Service, 2-4 weeks/yr, University of Colorado                        |
| 2020-present | Hospital  |
| 2016-present | Consult attending for Endocrine Inpatient Consult Service, 4-6 weeks/yr, University of                    |
|              | Colorado Hospital   |
| 2016         | First Course Health Disparities, Longitudinal Core Curriculum for 1st year medical                        |
|              | students: small group facilitator   |
| 2022-present | Lecturer, TREK Plains Curriculum (1st yr medical students): <i>Pathophysiology of Type 2</i>              |
|              | Diabetes (1 hr/yr)  |
| 2022-present | Lecturer, TREK Plains Curriculum (1st yr medical students): Treatment of Diabetes                         |
|              | (1.5  hr/yr)  |
| 2022-present | Case Lecturer and Facilitator, TREK Plains Curriculum (1st yr medical students):                          |
|              | Diabetes Complications (1.5 hr/yr)  |
|              |   |

### <u>Housestaff – Internal Medicine</u>

### **University of Utah School of Medicine**

Morning report 4 days/week, Morbidity and Mortality Conferences 2/month, 3<sup>rd</sup> and 4<sup>th</sup> year medical student EKG sessions weekly, medical service attending 7.5 weeks.

Organized departmental Grand Rounds and daily housestaff and medical student noon conferences

### **University of Colorado School of Medicine**

| 2001-2003      | Endocrine lectures and problem sessions for housestaff (monthly), Department of       |
|----------------|---|
|                | Medicine  |
| 2003-2004; 200 | 06-2009; Housestaff Noon Conference: Glycemic Emergencies; Also Inpatient             |
|                | Hyperglycemia Management, Department of Medicine                                      |
| 2003-2011      | Ward attending for Medical Service with housestaff teams, 2-4 weeks/yr, Denver VA     |
|                | Medical Center  |
| 2013-2015      | Ward attending for Medical Service with housestaff teams, 2 weeks/yr, University of   |
|                | Colorado Hospital   |
| 2003-present   | Consult Attending for Endocrinology Inpatient Consult Service, Department of Medicine |
| 2018-2019      | Housestaff Noon Conference: Inpatient Hyperglycemia and Diabetes Management, 1        |
|                | lecture/month, Department of Medicine   |

2020-present Housestaff Noon Conference: *Inpatient Hyperglycemia and Diabetes Management*, Department of Medicine

### Housestaff - Family Medicine

### **University of Colorado School of Medicine**

| 2009      | Diabetic neuropathy. Housestaff Conference. Department of Family Medicine          |
|-----------|--|
| 2014-2021 | Inpatient diabetes/hyperglycemia management, Family Medicine Housestaff Training   |
|           | Program Chautaqua intern lecture series  |
| 2016-2021 | Diabetic emergencies. Family Medicine Housestaff Training Program Chautaqua intern |
|           | lecture series   |

### **Housestaff and Fellows**

### **University of Colorado School of Medicine**

| 2003-2015    | Consult attending for Endocrine Inpatient Consult Service, 2-4 weeks/yr, University of |
|--------------|--|
|              | Colorado Hospital and Denver VA Medical Center   |
| 2013-present | Diabetes Clinical Conference, founder and organizer                                    |
| 2016-present | Consult attending for Endocrine Inpatient Consult Service, 4-6 weeks/yr, University of |
|              | Colorado Hospital  |
| 2019-present | Large Group Lectures. Residents and Fellows as Educators Elective, Academy of          |
|              | Medical Educators (May 2019, Dec 2019, Dec 2020, May 2021, Dec 2021).                  |

### **Interprofessional Education Program Students**

### **University of Colorado Anschutz Medical Campus**

2011-2013 Facilitator for Interprofessional Education Health Mentors Program – Schools of Medicine, Nursing, Pharmacy, Physician's Assistant, Physical Therapy, Dentistry

### **University of Colorado Health Nurses**

| 2016         | Inpatient Glucose Control, Half-day course for Obstetrics/Gynecology Registered           |
|--------------|---|
|              | Nurses, University of Colorado Hospital   |
| 2019-2020    | Inpatient Hyperglycemia and Diabetes Overview, Half-day course for Registered Nurses,     |
|              | Memorial Hospital, Colorado Springs, CO. Given twice a year.                              |
| 2019-present | Diabetes Overview, 1 hr lecture in a half-day course for Registered Nurses, University of |
|              | Colorado Hospital   |

### Clinical Fellows, Graduate and Undergraduate Students, Junior and Mid-Career Faculty

Framing. ENDO 2020, Virtual Meeting

# Endocrine Society Annual Meeting Career Development Workshops 2017 Promotion and Tenure/CV Writing. ENDO 2017, Orlando, FL 2018 Navigating Career Transitions: Lessons Learned as a New PI. ENDO 2018, Chicago, IL 2019 Personal Stories: Careers in Academia. Career Pathways. ENDO 2019, New Orleans, LA. 2019 Leadership Skills Lab: Conflict, Resolution, and Negotiation. ENDO 2019, New Orleans, LA. 2020 Difficult Conversations: Conflict Resolution and Negotiations. The Importance of

2021 Let's Talk: Science, Communication, and Social Media. ENDO 2021. Professional

Development Workshop. On-Demand, workshop number PDW05

### Endocrine Society Future Leaders Advancing Research in Endocrinology (FLARE) workshops

2021 Demystifying the Job Search and Negotiations. Virtual.

### **Endocrine Society Career Development Podcast Series**

2019 *Bouncing Back.* Episode 17 (ENP17). April 29, 2019.

https://www.endocrine.org/podcast/enp17-bouncing-back

### **Clinical Fellows**

### **American Diabetes Association Focus on the Fellows**

2020 Keep Your Career Path Options Open, Panelist. (Virtual)

# Barbara Davis Center for Diabetes DIALOG: DIABETES update and DIAbetes Technology Annual Workshop for EndocrinoLOGy Fellows

2018, 2019, 2021 Inpatient Diabetes. Lecture.

### Clinical Research Faculty, Clinical Research Associates and Staff

2015-2016 *Clinical Trial Design* lecture for Colorado Clinical Translational Science Institute Seminar Series.

### **KEY ADMINISTRATIVE POSITIONS**

### **University of Colorado School of Medicine**

| 2004-2019 | Director, Education Programs, Housestaff and Medical Students, Endocrinology,      |
|-----------|--|
|           | Metabolism and Diabetes, Department of Medicine                                    |
| 2008-2018 | Associate Director, Fellowship Program in Endocrinology, Metabolism, and Diabetes, |
|           | Department of Medicine   |

2008-2018 *Director*, Endocrine Elective, Division of Endocrinology, Metabolism and Diabetes, Department of Medicine

2019-present Director, Fellowship Program in Diabetes, Department of Medicine

# <u>TEACHING SCHOLARS PROGRAM</u>, University of Colorado Anschutz Medical Campus School of Medicine

2013-2014 Teaching Scholar. Project: Targeting Educational Gaps in Hospital Management of Diabetes and Stress Hyperglycemia with Resident Education. Presented at the 2015

University of Colorado Education Innovation Symposium (Feb 2015)

# <u>ACADEMY OF MEDICAL EDUCATORS</u>, University of Colorado Anschutz Medical Campus School of Medicine

2018 Selected for membership

2021 Co-Chair, Membership Committee

### **Mentorship**

### **Clinical Fellows**

| Fellowship in Endocrinology, Metabolism, and Diabetes, University of Colorado School of Medicine |  |
|--|--|
| 2005-2007  | Mentorship committee member for clinical endocrinology fellow.                       |
|  | Endocrinologist, Denver Endocrinology, Diabetes and Thyroid Center, Englewood, CO    |
| 2007-2009  | Mentorship committee member for clinical endocrinology fellow.                       |
|  | Endocrinologist, New West Physicians, Lakewood, CO                                   |
| 2010-2012  | Mentorship committee member for clinical endocrinology fellow.                       |
|  | Clinical Investigator, Institute for Health Research, Kaiser Permanente Colorado     |
|  | Affiliate Assistant Professor of Medicine, University of Colorado School of Medicine |
| 2012-2014  | Mentorship committee member for clinical endocrinology fellow.                       |
|  | Endocrinologist, The Austin Diagnostic Clinic, Austin, TX                            |
| 2013-2014  | Co-mentor for clinical endocrinology fellow.   |
|  | Endocrinologist, OhioHealth Endocrinology Physicians, Columbus, OH                   |
| 2014-2015  | Academic mentor for endocrinology faculty member.                                    |
|  | Endocrinologist, Kaiser Permanente, Honolulu, HI                                     |
| 2018-2021  | Mentorship Committee member for clinical endocrinology fellow.                       |
|  | University of Colorado School of Medicine  |
| 2019-2021  | Mentorship Committee member for clinical endocrinology fellow.                       |
|  | University of Colorado School of Medicine  |
| Fellowship in Pediatric Endocrinology, University of Colorado School of Medicine                 |  |
| 2016-2018  | Scholarly Oversight Committee member for pediatric endocrinology fellow.             |
|  | Instructor, Department of Pediatrics, University of Colorado School of Medicine      |
| 2018-2021  | Scholarly Oversight Committee member for pediatric endocrinology fellow.             |
|  | University of Colorado School of Medicine  |
| 2022-present   | Scholarly Oversight Committee member for pediatric endocrinology fellow, University  |
| _  | of Colorado School of Medicine   |
|  |  |

### **Doctor of Nurse Practitioner**

College of Nursing

| 2016-2018 | Committee member, Doctor of Nurse Practitioner candidate dissertation.     |
|-----------|--|
|           | Assistant Professor of Medicine, University of Colorado School of Medicine |
| 2017-2018 | Co-mentor, Doctor of Nurse Practitioner candidate dissertation.            |
|           | Instructor of Medicine, University of Colorado School of Medicine          |

## Learning Sessions completed – Academy of Medical Educators, University of Colorado SOM

| Dec 17, 2009   | Teaching in the Clinical Setting                             |
|----------------|--|
| Mar 15, 2010   | Public Speaking and PowerPoint Workshop                      |
| Apr 23, 2010   | Identification & Remediation of Struggling Students Workshop |
| Jul 22, 2010   | Mentor/Mentee Workshop                                       |
| Aug 24, 2010   | Better Bedside Teaching Workshop                             |
| Jan 6, 2011    | How to Build a Teacher's Portfolio                           |
| April 12, 2011 | Writing Test Questions                                       |
| May 17, 2011   | Team-Based Learning - Designing Group Work that Really Works |

| Dec 4, 2012 | Designing Clinical Cases for Teaching and Assessment |  |
|-------------|--|--|
| DCC 1, 2012 | Designing Chinear Cases for Teaching and Assessment  |  |

Jan 29, 2013 Leading Change Nov 12, 2013 Conflict Styles

Dec 6, 2018 Large Group Lectures

Dec 13, 2018 Mentorship

### **COMMUNITY OUTREACH and CLINICAL LECTURES**

| 2006-2016 | Type 1 Diabetes; Type 2 Diabetes; Hyperlipidemia; Management of obesity. Clinical   |
|-----------|---|
|           | Endocrinology for Primary Care Physicians, Continuing Medical Education conference, |
|           | Medical Education Resources, various locations in US: Oct 2006, Nov 2009, Dec 2012, |
|           | Aug 2014, Jul 2016, Sep 2016  |

- 2006-2008 Thyroid Disease in Women; Osteoporosis; Management of Obesity; Endocrine Cases. Issues in Women's Health for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources conferences, various locations in US: Dec 2006, Apr 2007, Jul 2007, Dec 2007, Jul 2008
- 2008-2009 Type 2 diabetes update on pathophysiology and treatment; Current management of thyroid disorders; Osteoporosis: recent developments; Case presentations Endocrinology. Internal Medicine for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, various locations in US and Caribbean: Mar 2008, Mar 2009, Dec 2009
- 2011-2012 <u>Eastern Colorado Health Care System SCAN-ECHO</u>: Tele-educational outreach program for care providers within the VISN 19 region. 45 minute lectures and case discussions on endocrine topics, targeted to primary care providers.

Jul 2011 Chronic kidney disease in diabetes
Aug 2011 Clinical management of hypothyroidism
Sep 2011 Issues in Vitamin D
May 2012 Osteoporosis

- 2016 May Type 1 diabetes; Type 2 diabetes; Disorders of Calcium Metabolism; Metabolic Bone Disease. Internal Medicine for Primary Care Physicians, Continuing Medical Education conference, Medical Education Resources, Grand Cayman
- 2016 Jun, Sep Type 2 diabetes mellitus; Disorders of Thyroid Function; Osteoporosis; Obesity

  Management Update. Internal Medicine for Primary Care Physicians, Continuing

  Medical Education conference, Medical Education Resources, Las Vegas, Cape Cod
- 2017 May Type 2 Diabetes; Insulin Therapy for Diabetes; Management of Dyslipidemia; Obesity Management Update. Internal Medicine for Primary Care: Endo/Geri/Psych/Rheum, Continuing Medical Education conference, Medical Education Resources, Key West, FL
- 2017 Jul Type 2 Diabetes; Insulin Therapy for Diabetes; Management of Dyslipidemia; Obesity Management Update. Internal Medicine for Primary Care: Cardio/Endo/Neuro/Pulm, Continuing Medical Education conference, Medical Education Resources, Maui, HI
- 2018 Sep. Type 2 Diabetes; Insulin Therapy for Diabetes; Thyroid Disease Update; Obesity Management Update. Internal Medicine for Primary Care: Cardio/ENT/ID/Endo, Continuing Medical Education conference, Medical Education Resources, Maui, HI
- 2019 Feb. Osteoporosis, Thyroid Disorders in Women, Obesity Management, Endocrine Cases.

Women's Health for Primary Care: Endo/Gyn/Psych, Medical Education Resources, Las Vegas, NV

2021 Jun Should metformin remain first-line therapy for type 2 diabetes? American Heart Association and American Diabetes Association Know Diabetes By Heart podcast.

### **Podcasts and Videos**

- (1) <u>Low Wang CC</u>. Diabetes: Nutrition and Sugar. Extended Interview (running time: 0:38:00) by Ambrose Digital Streaming Video. <a href="https://www.ambrosevideo.com/screening-room/163-dnx">https://www.ambrosevideo.com/screening-room/163-dnx</a>
- (2) Bakris G, Rasouli N, <u>Low Wang CC</u>. Should metformin remain first-line therapy for type 2 diabetes? American Heart Association and American Diabetes Association Know Diabetes By Heart podcast. <a href="https://www.knowdiabetesbyheart.org/podcast/2020-episode-3-metformin-is-it-always-first/">https://www.knowdiabetesbyheart.org/podcast/2020-episode-3-metformin-is-it-always-first/</a>

### **Key Interviews and Media**

- (1) <u>Low Wang CC</u>. UCHealth Today: A stem cell trial for diabetic foot ulcers. <u>https://www.uchealth.org/today/a-stem-cell-trial-for-diabetic-foot-ulcers/</u>
- (2) <u>Low Wang CC</u>. diaTribe Learn Making sense of diabetes: Hitting A Nerve: Introduction to Neuropathy, Last updated: 7/6/21. By Cheryl Alkon. <u>https://diatribe.org/hitting-nerve-introduction-neuropathy</u>
- (3) Reusch JEB. Featuring <u>Low Wang CC</u>. 2021 ADA General Highlights: GRADE Study, GIP/GLP-1 Receptor Agonists, Mental Health and Population Considerations in Diabetes, and More. VuMedi, 41 minutes.
- (4) <u>Low Wang CC</u>. Primary care diabetes fellowship. Healio/Endocrine Today. 2022 Dec29. https://www.healio.com/news/endocrinology/20211229/endocrinologists-propose-diabetes-fellowship-programs-to-address-growing-gap-in-care.
- (5) Close Concerns AACE 2022 Day #3 Highlights: DSN Year in Review.

### **BIBLIOGRAPHY**

I have publications under the surnames Low Wang, Wang, and Low. My surname is Low Wang.

### **Publications in Peer-reviewed Journals**

- 1) King CL, <u>Low CC</u>, and Nutman TB. IgE production in human helminth infection: Reciprocal interrelationship between IL-4 and IFN-γ. *J Immunol* 1993;150(5):1873-1880. PMID: 8094729.
- 2) <u>Low CC</u>, Grossman EB, and Gumbiner B. Potentiation of effects of weight loss by monounsaturated fatty acids in obese NIDDM patients. *Diabetes* 1996;45:569-575. PMID: 8621005.
- 3) Gumbiner B, <u>Low CC</u>, and Reaven PD. Effects of a monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients with type 2 diabetes. *Diabetes Care* 1998;21(1):9-15. PMID: 9538963.
- **4)** Wang CCL, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell phenotype and migration via distinct signaling pathways. *Diabetes* 2003;52:2562-2569. PMID: 14514641.

- 5) Hirshman E, Merritt P, <u>Wang CC</u>, Wierman M, Budescu DV, Kohrt W, Templin JL, Bhasin S. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. *Horm Behav* 2004;45(2):144-55. PMID: 15019802.
- 6) <u>Wang CC</u>, Goalstone M, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. *Diabetes* 2004;53:2735-2740. PMID: 15504952.
- 7) Wang CC, Sharma G, Draznin B. Egr-1 expression in vascular smooth muscle cells: effects of insulin and oxidative stress. *Am J Hyperten* 2006;19(4):366-372. PMID: 16580571.
- 8) Wang CC, Sorribas V, Sharma G, Levi M, Draznin B. Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. *Atherosclerosis* 2007;195:e65-e75. PMID: 17412344.
- 9) Reusch JEB, <u>Wang CC</u>. Cardiovascular disease in diabetes: Where does glucose fit in? *J Clin Endocrinol Metab* 2011;96:2367-2376. PMID: 21593112.
- 10) Pereira RI, Wang CC, Hosokawa P, Dickinson M, Neuman C, Karimkhani E, Erickson C, Chonchol M, Krantz M, Steiner JF, Besessen DH, Havranek EP, Long C. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease, independent of adiposity measures. *BMC Endocr Disord* 2011;11:13. doi:10.1186/1472-6823-11-13. PMID: 21736747.
- 11) Draznin B, <u>Wang C</u>, Adochio R, Leitner JW, Cornier M-A. Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. *Horm Metab Res* 2012;44(09):650-655. PMID 22674476.
- **12)** Reusch JEB, <u>Wang CC</u>. Type 2 Diabetes in the Federal Health Care Setting: Optimizing Patient Outcomes in Diabetes Management. Article 2: Management of comorbidities and risk factors including hypoglycemia. *Fed Pract* 2012;29(Suppl. 1):8S-13S.
- **13)** Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, <u>Wang C</u>, Kam I, Draznin B. Subcutaneous Administration of Glargine to Diabetic Patients Receiving Insulin Infusion Prevents Rebound Hyperglycemia. *J Clin Endocrinol Metab* 2012;97(9):3132-3137. PMID 22685233.
- **14)** Rasouli N, Seggelke S, Hawkins RM, Gibbs J, Casciano ML, Cohlmia E, Taylor-Cousar J, <u>Wang C</u>, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes: inpatient management of 121 patients during 410 admissions. *J Diab Sci Technol* 2012;6(5):1038-1044. PMID: 23063029.
- **15)** Wang CC, Reusch JEB. Cardio-Diabetes: Special Considerations for Patients with Diabetes and Cardiovascular Disease. Diabetes and Cardiovascular Disease: Changing the Focus from Glycemic Control to Improving Long Term Survival. *Am J Cardiol* 2012;110(9 Suppl):58B-68B. PMID: 23062569.

- **16)** Wang CC, Adochio R, Leitner JW, Abeyta I, Draznin B, Cornier MA. Effects of a high fat, low carbohydrate versus a low fat, high carbohydrate hypocaloric diet on skeletal muscle insulin signalling in obese individuals. *Metabolism* 2013;62(4):595-603. PMID: 23174405.
- 17) <u>Low Wang CC</u>, Xu Y, Lu L, Leitner JW, Gunter J, Sarraf M, Draznin B, Greyson CR, Reusch JEB, Schwartz GG. Arterial insulin resistance in Yucatan micropigs with diet-induced obesity and metabolic syndrome. *J Diabetes Complic* 2013;27(4):307-15. http://dx.doi.org/10.1016/j.jdiacomp.2013.02.009. PMID: 23558108.
- **18)** <u>Low Wang CC</u>, Draznin B. Practical Approach to Management of Inpatient Hyperglycemia Management in Selected Populations. *Hosp Pract* (1995). 2013;41(2):45-53. doi: 10.3810/hp.2013.04.1025. PMID: 23680736.
- 19) <u>Wang CCL</u>, Draznin B. Insulin use in hospitalized patients with diabetes: Navigate with care. *Diabetes Spect* 2013; 26(2):124-130. <a href="http://dx.doi.org/10.2337/diaspect.26.2.124">http://dx.doi.org/10.2337/diaspect.26.2.124</a>
- 20) Draznin B, Gilden J, Golden SH, and Inzucchi SE for the PRIDE investigators: Baldwin D, Bode BW, Boord JB, Braithwaite SS, Cagliero E, Draznin B, Dungan KM, Falciglia M, Figaro MK, Gilden J, Golden SH, Hirsch IB, Klonoff D, Korytkowski MT, Kosiborod M, Lien LF, Magee MF, Masharani U, Maynard G, McDonnell ME, Moghissi ES, Rasouli N, Rubin DJ, Rushakoff RJ, Sadhu AR, Schwartz S, Seley JJ, Umpierrez GE, Vigersky RA, Low CC, Wexler DJ. Pathways to Quality Inpatient Management of Hyperglycemia and Diabetes: A Call to Action. *Diabetes Care* 2013;36:1807-1814. PMID: 23801791.
- **21)** Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, <u>Wang CC</u>, Draznin B. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. *Endocr Pract* 2014;20(6):536-9. doi: 10.4158/EP13404.OR. PMID: 24326004.
- **22)** Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, <u>Wang C</u>, Draznin B. Transitional Care Clinic for Uninsured and Medicaid covered Patients with Diabetes Discharged from the Hospital May Reduce Re-admissions: A Pilot Quality Improvement Study. *Hosp Pract* (1995) 2014;42(1):46-51. doi: 10.3810/hp.2014.02.1091. PMID: 24566596.
- **23)** Draznin B, Wang Y, Seggelke S, Hawkins RM, Gibbs J, Bridenstine M, Rasouli N, <u>Wang CL</u>. Glycemic control and outcomes of hospitalization in noncritically ill patients with type 2 diabetes admitted with cardiac problems or infections. *Endocr Pract* 2014 Dec;20(12):1303-8. doi: 10.4158/EP14174.OR. PMID: 25100383.
- **24)** <u>Low Wang CC</u>, Galinkin JL, Hiatt WR. Toxicity of a novel therapeutic agent targeting mitochondrial complex I. *Clin Pharmacol Ther* 2015;98(5):551-559. doi: 10.1002/cpt.178. PMID: 26108785.

- **25)** Pereira RI, <u>Low Wang CC</u>, Wolfe P, Havranek EP, Long CS, Bessesen DH. Associations of adiponectin with adiposity, insulin sensitivity, and diet in young, healthy, Mexican Americans and non-Latino white adults. *Int J Envir Res Public Health* 2015;13(1):ijerph13010054. doi: 10.3390/ijerph13010054. PMID: 2670368.
- **26)** Jensen T, <u>Low Wang CC</u>. Double trouble: A case of primary hyperparathyroidism and humoral hypercalcemia of malignancy secondary to epithelioid angiosarcoma occurring in a single patient. *AACE Clinical Case Reports* 2016, Vol. 2, No. 2, pp. e146-e150. doi: http://dx.doi.org/10.4158/EP15768.CR.
- **27)** <u>Low Wang CC</u>, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus Mechanisms, Management, and Clinical Considerations. *Circulation* 2016;133(24):2459-2502. doi: 10.1161/CIRCULATIONAHA.116.022194. PMID: 27297342.
- **28)** Wallia A, Umpierrez GE, Nasraway SA, Klonoff DC; PRIDE Investigators. Round Table Discussion on Inpatient Use of Continuous Glucose Monitoring at the International Hospital Diabetes Meeting. *J Diabetes Sci Technol* 2016;10(5):1174-1181. doi: 10.1177/1932296816656380.PMID: 27286715.
- **29)** Wang YJ, Seggelke S, Hawkins RM, Gibbs J, Lindsay M, Hazlett I, <u>Low Wang CC</u>, Rasouli N, Young KA, Draznin B. Impact of Glucose Management Team on Outcomes of Hospitalization in Patients with Type 2 Diabetes Admitted to the Medical Service. *Endocr Pract* 2016;22(12):1401-1405. PMID: 27540884.
- **30)** Seggelke SA, Lindsay MC, Hazlett I, Sanagorski R, Eckel RH, <u>Low Wang CC</u>. Cardiovascular safety of antidiabetic drugs in the hospital setting. *Curr Diab Rep* 2017; 17:64. PMID: 28699089.
- **31)** Hess CN, <u>Low Wang CC</u>, Hiatt WR. PCSK9-inhibitors: Mechanisms of action, metabolic effects, and clinical outcomes. *Ann Rev Med* 2018;69:133-145. PMID: 29095667.
- 32) Rogers RK, Hiatt WR, Patel MR, Shishehbor MH, White R, Khan ND, Bhalla NP, Jones WS, <u>Low Wang CC</u>. Ticagrelor in Peripheral Artery Disease Endovascular Revascularization: Challenges in Clinical Trial Execution. *Vascular Med* 2018;23(6):513-522. PMID: 29629845.
- 33) <u>Low Wang CC</u>, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, and Hiatt WR, on behalf of the EUCLID Trial Executive Committee and Investigators. Cardiovascular and Limb Outcomes in Patients with Diabetes and Peripheral Artery Disease: the EUCLID Trial. *J Am Coll Cardiol* 2018;72(25):3274-3284. PMID: 30573030.
- **34)** Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J 2018;199:83-91.

- https://doi.org/10.1016/j.ahj.2018.01.011. PMID: PMID: 32222135. Cited in Supplementary Material: Member of Independent Clinical Adjudication Committee (ICAC).
- **35)** <u>Low Wang CC</u>, Everett BM, Burman KD, Wilson PWF. Cardiovascular safety trials for all new diabetes mellitus drugs? Ten years of FDA guidance requirements to evaluate cardiovascular risk. *Circulation* 2019;139:1741-1743. PMID: 30933621.
- **36)** Vellanki P, Rasouli N, Baldwin S, Alexanian S, Anzola I, Urrutia M, Cardona S, Peng L, Pasquel FJ, Umpierrez GE, Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to a basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: A multicentre randomized clinical trial. *Diabetes Obes Metab* 2019;21(4):837-843. doi: 10.1111/dom.13587. PMID: 30456796. Acknowledged as a collaborator in the Linagliptin Inpatient Research Group who contributed to the recruitment and care of study participants and collected data.
- 37) Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. *N Engl J Med* 2020;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. PMID: 32222135. Cited in Appendix: Member of CPC Study Team and of the Independent Clinical Adjudication Committee (ICAC).
- **38)** Shubrook JH, Ramirez BF, Healy AM, Salzberg L, Ahmed S, Feinberg H, Schutta M, Schwartz FL, Low Wang CC. Primary Care Diabetes Fellowship Programs: Developing National Standards. *Clin Diabetes* 2020. https://doi.org/10.2337/cd20-0055. PMID: 33551558.
- **39)** Seggelke SA, Ingram CI, Crawley S, <u>Low Wang CC</u>. Insulin Resistance in a Hospitalized COVID-19 Patient: A Case Review. *Clin Diabetes* 2021;9(2):228-232. <a href="https://doi.org/10.2337/cd20-0036">https://doi.org/10.2337/cd20-0036</a>. PMID: 33986579.
- **40)** Govsyeyev N, Nehler MR, <u>Low Wang CC</u>, Kavanaugh S, Hiatt WR, Long C, Jones WS, Fowkes FGR, Berger JS, Baumgartner I, Patel MR, Goodney PP, Beckman JA, Katona BG, Mahaffey KW, Blomster J, Norgren L, Bonaca MP. Etiology and Outcomes of Amputation in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. *J Vasc Surg* 2021; S0741-5214(21)02161-3. doi: 10.1016/j.jvs.2021.08.096. PMID: 34597783.
- **41)** Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, <u>Low Wang CC</u>. Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review. *Endocr Pract* 2022; *in press*.

- Draznin B (ed.), <u>Low Wang CC</u> (associate editor) and Rubin D (associate editor). Diabetes Case Studies: Real Problems, Practical Solutions. American Diabetes Association, Inc. Alexandria, VA. 2015.
- 2) <u>Low Wang CC</u> and Shah A (co-editors). Medical Management of Type 1 Diabetes, 7th edition. American Diabetes Association, Inc. Alexandria, VA. 2017.

### **Book Chapters**

- Jones RE, <u>Wang CCL</u>. Ch. 31 Adrenal insufficiency. *In* <u>Endocrine Secrets</u>, 4<sup>th</sup> edition, 2005. (ed.) McDermott MT. Elsevier Mosby, Philadelphia.
- 2) <u>Wang CCL</u>. Chapter 12. Insulin resistance and cardiovascular disease. *In* <u>Insulin Resistance and Metabolic Syndrome: Childhood Precursors and Adult Disease</u> from the *Contemporary Endocrinology Series*, 2008. Humana Press, New Jersey
- **3)** Wang CCL, Grotzke M, Jones RE. Ch. 30: Adrenal insufficiency. *In* Endocrine Secrets, 5<sup>th</sup> edition, 2009. (ed.) McDermott MT. Mosby Elsevier, Philadelphia.
- **4)** Schroeder E, <u>Wang CCL</u>. Ch. 30: Adrenal insufficiency. *In* <u>Endocrine Secrets</u>, 6<sup>th</sup> edition, 2013. (ed.) McDermott MT. Saunders, Philadelphia.
- 5) <u>Low Wang CC</u>. Case 15: Type 1 Diabetes versus LADA in a Patient Misdiagnosed with Type 2 Diabetes. *In* <u>Diabetes Case Studies: Real Problems, Practical Solutions.</u> Draznin B, Low Wang CC, Rubin DJ, Eds. Alexandria, VA, American Diabetes Association, 2015, pp. 58-60.
- 6) <u>Low Wang CC</u>, Hawkins RM, Gianchandani R, Dungan K. Chapter 6: Glycemic control in the setting of Parenteral Nutrition or Enteral Nutrition Via Tube Feeding. *In:* <u>Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide</u>. American Diabetes Association, Inc. Alexandria, VA. 2016.
- 7) Lien L, <u>Low Wang CC</u>, Kreider KE, Baldwin D. Chapter 8: Transitioning from intravenous to Subcutaneous insulin. *In Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide*. American Diabetes Association, Inc. Alexandria, VA, 2016.
- 8) Rushakoff R, <u>Low Wang CC</u>, Seley J, Warnock A. Chapter 29: Resident Education. *In*: <u>Managing Diabetes and Hyperglycemia in the Hospital Setting: A Clinician's Guide</u>. American Diabetes Association, Inc. Alexandria, VA. 2016.
- 9) <u>Low Wang CC</u>, Galinkin JL, Hiatt WR. Chapter 38: Lessons Learned from a Phase I Clinical Trial of Mitochondrial Complex I Inhibition. *In*: <u>Mitochondrial Dysfunction by Drug and Environmental Toxicants.</u> (eds) Yvonne Will and James A. Dykens. John Wiley & Sons, Inc. Hoboken, NJ. 2018.

- **10)** <u>Low Wang CC</u>, Draznin B. Part II. Chapter 2. Insulin resistance: Molecular Biology and Pathophysiology. *In* <u>Atypical Diabetes: Pathophysiology, Clinical Presentations, and Treatment Options</u>. American Diabetes Association, Inc. Arlington, VA. 2018.
- 11) Zaman A, <u>Low Wang CC</u>. Chapter 1: Diabetes Mellitus: Etiology, Classification, and Diagnosis. *In* Endocrine Secrets, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- **12)** <u>Low Wang CC</u>, Zaman A. Chapter 2: Diabetes Mellitus: Acute and Chronic Complications. *In* <u>Endocrine Secrets</u>, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- 13) Zaman A, <u>Low Wang CC</u>. Chapter 5: Diabetes Technology: Pumps, Sensors and Beyond. *In* <u>Endocrine Secrets</u>, 7<sup>th</sup> edition. Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- **14)** Schroeder E, <u>Low Wang CC</u>. Ch. 36: Adrenal insufficiency. *In* <u>Endocrine Secrets</u>, 7<sup>th</sup> edition, Elsevier, Inc., St. Louis, MO. 2019. (ed.) McDermott MT.
- **15)** Hawkins RM, Adair WB, Gibbs J, Vinh J, <u>Low Wang CC</u>. Part 8, Chapter 42: Transient Severe Insulin Resistance in COVID-19 and Prediabetes. *In* <u>Diabetes in Practice Case Studies with Commentary</u>. (ed.) Draznin B. Alexandria: American Diabetes Association, 2021.
- **16)** <u>Low Wang CC</u>. Part 8, Chapter 47: Coincidence or Consequence? A Case of Type 1 Diabetes with Worsening Neuropathy. *In* <u>Diabetes in Practice Case Studies with Commentary</u>. (ed.) Draznin B. Alexandria: American Diabetes Association, 2021.
- **17)** <u>Low Wang CC</u>, Seggelke SA, McDermott MT, Reusch JEB. Chapter 2: Pathophysiology: How COVID-19 Impacts the Pancreas and Peripheral Insulin Resistance. *In* <u>Diabetes and COVID-19</u>: Considerations and Clinical Management (Springer; ed. Alyson K Myers). *Submitted*.
- **18)** Everett BM, Pagidipati N, <u>Low Wang CC</u>. Regulatory Approach to Medications for Type 2 Diabetes: Past, Present and Future. *In:* <u>Diabeto-Cardiology: A Companion to Braunwald's Heart Disease</u>. (Elsevier; ed. Darren McGuire). *Submitted*.

### **Editorials and Commentaries**

- 1) Draznin B, Gilden J, Golden SH, Inzucchi S; PRIDE Investigators. Response to comment on: Draznin et al. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. *Diabetes Care* 2013;36(12):e220. doi: 10.2337/dc13-1855. PMID: 24265389.
- **2)** Low Wang CC, Draznin B. Use of NPH Insulin for Glucocorticoid-Induced Hyperglycemia. *Endocr Pract* 2016;22(2):271-273. doi: 10.4158/EP151101.CO. PMID: 26789338.
- 3) <u>Low Wang CC</u>, Michels AW. The Missing Link for Cardiovascular Disease in Type 1 Diabetes Mellitus? Hyperglycemia-induced Cardiac Autoimmunity. Expert Analysis for American College of Cardiology website: Diabetes and Cardiometabolic Disease Clinical Topic Collection. <a href="http://www.acc.org">http://www.acc.org</a>. Jul 25, 2019. Accessed Aug 23, 2019. Available at:

- https://www.acc.org/latest-in-cardiology/articles/2019/07/25/10/49/the-missing-link-for-cardiovascular-disease-in-type-1-diabetes-mellitus.
- **4)** Draznin B, Sadhu A, Schutta M, Ramirez BF, Polsky S, Shubrook JH, <u>Low Wang CC</u>. The Diabetes Epidemic and Diabetes Fellowships for Primary Care Physicians. Endocr Pract 2021;27(6):636-637. doi: 10.1016/j.eprac.2021.03.007. PMID: 33757910. <a href="https://doi.org/10.1016/j.eprac.2021.03.007">https://doi.org/10.1016/j.eprac.2021.03.007</a>.
- 5) Draznin B, Sadhu A, Schutta M, Ramirez BF, Polsky S, Shubrook JH, <u>Low Wang, CC</u>. Authors' Reply: Improved Access to Quality Diabetes Care in the United States: Where Do We Go From Here? *Endocr Pract* 2021;27(7):760-761. doi: 10.1016/j.eprac.2021.04.883. PMID: 33940181. https://doi.org/10.1016/j.eprac.2021.04.883.

### Other

- 1) <u>Wang CC</u>, Wierman ME. Positron emission tomography scanning for ectopic Cushing's Syndrome. *EndoTrends* 2003;10(1):6-9.
- 2) <u>Low Wang CC</u> and Draznin B. Inpatient Management of Patients with Diabetes. *First Consult, MD Consult* Web site available at www.mdconsult.com. Posted September 11, 2013. Accessed September 11, 2013.
- 3) <u>Low Wang CC</u>. Diabetes and immunizations. *Physicians' Weekly*. 2014. http://www.physiciansweekly.com/keeping-up-vaccinations-people-with-diabetes/
- **4)** <u>Low Wang CC</u>. Diabetic neuropathy. *Physicians' Weekly*. 2014. <u>http://www.physiciansweekly.com/taking-proactive-approach-diabetic-neuropathy/</u>
- 5) <u>Low Wang CC</u>. Diabetes and Cardiovascular Disease. *Physicians' Weekly*. 2015. <u>http://www.physiciansweekly.com/cme-cardiometabolic-risk-type-2-diabetes-heart-disease/</u>
- **6)** Low Wang CC. Syllabus. Inpatient Hyperglycemia. *Endocrine Society Meet the Professor Handbook*. 2017.
- 7) <u>Low Wang CC</u>. Commentary for <u>www.PracticeUpdate.com</u> on *Diabetes Care* article: The Presence of Diabetes and Higher HbA1c Are Independently Associated With Adverse Outcomes After Surgery. Available at: <a href="https://www.practiceupdate.com/content/diabetes-and-higher-hba1c-levels-are-independently-associated-with-adverse-postsurgical-outcomes/66074/62">https://www.practiceupdate.com/content/diabetes-and-higher-hba1c-levels-are-independently-associated-with-adverse-postsurgical-outcomes/66074/62</a>. Accessed September 7, 2018.
- 8) <u>Low Wang CC.</u> Commentary for <u>www.PracticeUpdate.com</u> on *Lancet Diabetes and Endocrinology* article: Association of Preoperative Glucose Concentration With Myocardial Injury and Death After Non-ardiac Surgery (GlucoVISION): A Prospective Cohort Study. Available at: <a href="http://www.practiceupdate.com/content/association-of-preoperative-glucose-concentration-with-myocardial-injury-and-death-after-noncardiac-surgery/71372/65/8/1">http://www.practiceupdate.com/content/association-of-preoperative-glucose-concentration-with-myocardial-injury-and-death-after-noncardiac-surgery/71372/65/8/1</a>. Accessed August 15, 2018.
- 9) <u>Low Wang CC</u>. Commentary for <u>www.PracticeUpdate.com</u> on *Diabetes Care* article: A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial. PracticeUpdate website. Available at: <a href="https://www.practiceupdate.com/content/comparing-glargine-u300-and-glargine-u100-for-the-inpatient-management-of-patients-with-type-2-diabetes/98993/65/8/1">https://www.practiceupdate.com/content/comparing-glargine-u300-and-glargine-u100-for-the-inpatient-management-of-patients-with-type-2-diabetes/98993/65/8/1</a>. Accessed April 29, 2020
- **10)** <u>Low Wang CC</u>, McRae M. Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide versus Glargine Insulin for the Management of

- Patients with Type 2 Diabetes After Hospital Discharge. PracticeUpdate website. Available at: <a href="https://www.practiceupdate.com/content/liraglutide-hospital-discharge-trial/114021/65/8/1">https://www.practiceupdate.com/content/liraglutide-hospital-discharge-trial/114021/65/8/1</a>. Accessed March 12, 2021.
- 11) Low Wang CC. A commentary on: A Randomised Controlled Trial Comparing Insulin Degludec U100 and Glargine U100 for the Inpatient Management of Patients with Type 2 Diabetes. PracticeUpdate website. Available at: https://www.practiceupdate.com/content/insulin-degludec-u100-vs-glargine-u100-for-inpatient-type-2-diabetes-management/123568/65/8/1. Accessed September 29, 2021.

### **Selected Abstracts**

- 1) <u>Low CC</u>, King CL, Klion A, Nutman TB. Cytokine Production in Patients with Helminth Infection in Relation to IgE Synthesis. NIAID Summer Student Program Poster Session 1990. Poster.
- 2) <u>Low CC</u>, Ilgen C, King CL. Cytokine Production as related to IgE Synthesis in Patients with Helminth Infection. EUREKA National Conference on Undergraduate Research 1991. Poster.
- 3) Langsam AL, <u>Low CC</u>, Madden KS, Felten SY, Felten DL, Bellinger DL. The Effect of Chemical Sympathectomy on Primary Antibody Response in Young and Old F344 Rats. Society for Neurosciences Abstracts 1993;19:944(388.1).
- **4)** <u>Low CC</u>, Gumbiner B. Monounsaturated Fatty Acids Potentiate the Metabolic Effects of Dieting in Obese NIDDM. Journal of Investigative Medicine 1995;42(1)Supp.1:135A.
- 5) <u>Low CC</u>, Gumbiner B. Increased Insulin Secretion and Improved Glycemic Control by High Monounsaturated Fatty Acid (MUFA) vs. High Carbohydrate (CHO) Hypocaloric Diet in Obese Noninsulin-Dependent Diabetes Mellitus. *Diabetes* 1995;44(Supp. 1):8A, Abstract 21.
- 6) Grossman EB, <u>Low CC</u>, Gumbiner B. Differential Effects of Monounsaturated Fat (MUFA) and High Carbohydrate-Induced Weight Loss on Insulin and Blood Pressure (BP). *Journal of the American Society of Nephrology* 1995;6(3):641, Abstract 772.
- 7) <u>Wang CCL</u>, Draznin B. Phenotypic Modulation of Vascular Smooth Muscle Cells by Insulin: The Role of Phosphatidylinositol 3-kinase. *J Investig Med* 2002;50(1):51A, Abstract 277.
- **8)** Wang CCL, Draznin B. Phosphatidylinositol 3-kinase Modulates the Effect of Insulin on Vascular Smooth Cell Phenotype. *Diabetes* 2002;51(Supp. 2):A181, Abstract 732.
- 9) Wang CCL, Golovchenko I, Draznin B. Vascular Smooth Muscle Cell Quiescence and Migration Are Mediated Differentially Via Phosphatidylinositol 3-Kinase- and Mitogen-Activated Kinase-Dependent Pathways. *J Investig Med* 2003;51 Supp.1:S162, Abstract 403.
- **10)** Wang CCL, Golovchenko I, Draznin B. Vascular smooth muscle cell quiescence and migration are mediated differentially via phosphatidylinositol 3-kinase- and mitogen-activated kinase-dependent pathways. *Diabetes/Metabolism Research and Reviews* 2003;19(2):S5, 2774.

- 11) <u>Wang CCL</u>, Gurevich I, Draznin B. Insulin affects vascular smooth muscle cell quiescence and migration via distinct signaling pathways. *Diabetes* 2003;52(Supp.1):A182, 780-P.
- **12)** Wang CCL, Draznin B. Insulin and oxidative stress have additive effects on Egr-1 in vascular smooth muscle cells. Endocrine Society Annual Meeting Abstract Book 2004, poster 1-89.
- 13) Wang CCL, Draznin B. Signaling pathways mediating the effects of insulin and oxidative stress on Egr-1 expression in vascular smooth muscle cells. Keystone Symposium: The Cellular Biology of Atherosclerosis 2005, poster 320.
- **14)** Wang CCL, Draznin B. Insulin and oxidant stress effects on early growth response gene-1 expression are mediated differently in vascular smooth muscle cells. *J Investig Med* 2005;53 Supp.1:S105, Abstract 159.
- **Wang CCL**, Sorribas V, Sharma G, Levi M, Draznin B. Insulin-mediated increase in vascular smooth muscle cell phosphate transport may be associated with vascular calcification in insulin resistance. *Diabetes* 2005;54(Supp.1):A192, 783-P.
- **16)** Wang CCL, Sorribas V, Sharma G, Levi M, Draznin B. Insulin attenuates VSMC calcification but increases VSMC phosphate transport. Keystone Symposium: Metabolic Syndrome and Cardiovascular Risk 2007, poster 340.
- 17) Wang CCL, Draznin B, Leitner JW, Jorgenson S, Lu L, Ya X, Greyson C, Schwartz G, Reusch JEB. Aortic insulin signaling is perturbed in a large animal model of diet-induced obesity. *J Investig Med* 2008;56(1):190, Abstract 262.
- **18)** Wang CCL, Draznin B, Leitner JW, Jorgensen S, Lu L, Xu Y, Greyson CR, Reusch JE, Schwartz GG. Disruption of insulin signaling in a large animal model of diet-induced obesity. *Diabetes* 2008;57(Supp.1):A475,1709-P.
- **19)** Schwartz GG, Draznin B, Reusch JEB, Leitner JW, Lu L, Xu Y, Greyson CR, <u>Wang CCL</u>. Insulinstimulated PI 3-kinase activity is blunted, but Akt phosphorylation is preserved in aortas of pigs with diet-induced obesity. *J Am Coll Cardiol* 2009;53(10,Supp. 1):A435. Poster 1031-102.
- **20)** Wang CCL, Pereira RI, Benton K, Dickinson M, Estacio R, Krantz M, Neuman C, Long C, Havranek E, Chonchol M. Association between 25-hydroxyvitamin D levels and insulin resistance in hypertensive subjects. *14*<sup>th</sup> Workshop on Vitamin D abstract book 2009.
- **21)** Wang CCL, Pereira RI, Benton KL, Dickinson LM, Estacio RO, Krantz MJ, Neuman C, Long CS, Havranek E and Chonchol MB. Vitamin D levels and insulin resistance in a mostly Latino hypertensive cohort. *J Am Soc Nephrol* Abstracts Issue 20:2009, p 644A. SA-PO2335.

- **22)** Wang CCL, Lu L, Xu Y, Greyson C, Jacobs S, Reusch JEB, Gianani R, Draznin B, Schwartz G. Diet-induced insulin resistance causes isoform-specific abnormalities of Akt signaling in arterial wall of pigs. *Circulation* 2009;120(18 Supp): S443-S444, Abstract 1087.
- **23)** Wang CCL, Gunter J, Leitner JW, Lu L, Xu Y, Greyson C, Gianani R, Draznin B, Reusch JEB, Schwartz GG. Early defects occur in PI3-kinase/Akt signaling and vascular function in a novel porcine model of diet-induced obesity. *Diabetes* 2010;59(Supp 1):A66, oral presentation 249-OR.
- **24)** Wang CCL, Pereira RI, Hosokawa P, Dickinson LM, Krantz M, Neuman C, Long C, Chonchol M, Havranek E. Association between 25-hydroxyvitamin D and adiponectin levels in hypertensive subjects. *Diabetes* 2010;59(Supp 1):A225, poster 828-P.
- **25)** Wang CCL, Xu Y, Leitner JW, Lu L, Draznin B, Greyson C, Reusch JEB, Schwartz GG. Blunted Vascular PI3-Kinase Signaling in a Novel Porcine Model of Diet-Induced Obesity Is Due to Increased Total P85alpha and Is Accompanied by Vascular Dysfunction. *Endocr Rev* 2011;32(03\_MeetingAbstracts):P3-377.
- **26)** Wang CCL, Seggelke S, Hawkins RM, Cohlmia E, Gibbs J, Rasouli N, and Draznin B. Transitional Care Clinic for Patients with Diabetes May Prevent Re-Hospitalizations. *Diabetes* 2013;July supplement. 1217-P. Selected for Guided Audio Poster Tour.
- **27)** Seggelke S, Hawkins RM, Gibbs J, Cohlmia E, Rasouli N, <u>Wang CCL</u>, and Draznin B. Effects of Glargine Insulin Delivery Method (Pen-Device vs. Vial-Syringes) on Glycemic Control and Patient Preferences. *Diabetes* 2013; July supplement. 988-P.
- **28)** Schauer I\*, <u>Wang CCL\*</u>, Bridenstine M, Durbin R, Herlache L, Regensteiner J and Reusch JEB. Rosiglitazone improves C-reactive protein and liver function in impaired glucose tolerance but not coronary artery calcification or exercise function. *Diabetes* 2013; July supplement. 2337-PO. \*indicates co-first author
- 29) Wang YJ, Hawkins RM, Seggelke S, Gibbs J, <u>Wang CCL</u>, Draznin B. Optimal Glycemic Control Improves Clinical Outcomes in Patients with Type 2 Diabetes. *Diabetes* 2013; July supplement. 86-LB.
- **30)** Jensen T, <u>Low Wang CC</u>. Double trouble: A case of primary hyperparathyroidism and humoral hypercalcemia of malignancy. *Endocr Rev* 2014;35(3 Suppl), poster SAT-0202.
- **31)** Schwartz GG, Leitner JW, Lu L, Ye S, Pendyal A, Pereira R, <u>Wang CC</u>, Reusch JE, Greyson CR. Depot-specific abnormalities in adipose tissue insulin signaling in a porcine model of metabolic syndrome. *In* Core 2. Epidemiology and Prevention of CV Disease: Physiology, Pharmacology and Lifestyle Session Title: Diabetes Mellitus and CVD: Prevention and Management V. *Circulation* 2014;130(Supplement 2), A12109.

- **32)** <u>Low Wang CC</u>, Anderson M. Targeting gaps in hospital management of diabetes and stress hyperglycemia with resident education. 2015 University of Colorado Education Innovation Symposium.
- **33)** <u>Low Wang CC</u>, Sanagorski R, Hawkins RM, Gibbs J, Tompkins K, Bridenstine M, Seggelke S, Draznin B. Impact of Subcutaneous Detemir Insulin on Rebound Hyperglycemia in Hospitalized Patients with Diabetes Transitioning From a Continuous Intravenous Insulin Infusion. Endocrine Society Annual Meeting 2015. Poster Preview PP01-2. Poster number THR-662.
- **34)** Thompson E, Everhart B, <u>Low Wang C</u>. Reduction of Hyperglycemia on a Medical Unit Using a Focused, Multi-Disciplinary Partnership. University of Colorado Health Research Symposium 2017.
- 35) Blomster JL, <u>Low Wang CC</u>, Heizer G, Berger JS, Baumgartner I, Fowkes GR, Held P, Katona BG, Norgren L, Jones WS, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR on behalf of the EUCLID Trial Executive Committee and Investigators. Diabetes and Cardiovascular Risk in Patients with Symptomatic Peripheral Artery Disease. European Society of Cardiology Congress 2017. *Eur Heart J* 2017;38(Supplement):1080. Poster session 6: Vascular diseases -2; Peripheral artery disease pathophysiology, epidemiology, diagnosis. P5193.
- **36)** Keshawarz A, Alman A, <u>Low Wang CC</u>, Mitchell S, Schauer IE, Reusch JEB, Regensteiner JG, Snell-Bergeon JK. Visceral and subcutaneous adipose tissue attenuation differs by type 1 and type 2 diabetes status. American Diabetes Association 79<sup>th</sup> Scientific Sessions. *Diabetes* 2019;68(Supplement 1): 1471-P. https://doi.org/10.2337/db19-1471-P.
- 37) Behan S, <u>Low Wang CC</u>, Hess C, Mulder H, Gutierrez A, Fowkes F, Baumgartner I, Berger J, Katona B, Mahaffey K, Norgren L, Blomster J, Jones S, Patel MR, Hiatt WR, Bonaca MP. Polyvascular disease with and without diabetes and the risk of adverse cardiovascular and limb events in the EUCLID trial. *J Am Coll Cardiol* 2020. 40. Vascular medicine: Non coronary arterial disease. 20-A-14515-ACC.
- **38)** Mayson SE, Haugen B, <u>Low Wang CC</u>. The Endocrinology Fellowship Thyroid/Neck Ultrasound Curriculum Innovations Project. 2020 AME Education Symposium. University of Colorado Anschutz Medical Campus, Aurora, CO.
- **39)** Zaman A, McDermott MT, Mansfield V, <u>Low Wang CC</u>. Mortality in Patients with Glucose Derangements after ICU Admission. American Diabetes Association's 80th Scientific Sessions 2020 Virtual. 1611-P in category 16-F Epidemiology—Other.
- **40)** Govsyeyev N, Nehler MR, <u>Low Wang CC</u>, Kavanagh S, Hiatt WR, Long C, Jones WS, Fowkes FG, Berger JS, Patel MR, Katona B, Norgren L and Bonaca MP. Amputation in Patients With PAD With and Without Diabetes: Insights From the EUCLID Trial. American Heart Association Scientific Sessions 2020 Virtual. Circulation 2020;142(Suppl\_3):Abstract 16512.

- 41) Hawkins RM, Seggelke S, Gibbs J, Lindsay M, <u>Low Wang CC</u>. Glycemic Control in Hospitalized Patients Receiving Enteral Nutrition. American Diabetes Association 81<sup>st</sup> Scientific Sessions 2021 (virtual). Poster #2021-A-5827-Diabetes. *Diabetes* 2021;70(Supplement 1):825-P. <a href="https://doi.org/10.2337/db21-825-P">https://doi.org/10.2337/db21-825-P</a>.
- **42)** Low Wang CC, Nehler M, Lloyd Haskell, Scott D Berkowitz, E. Sebastian Debus, Rupert Bauersachs, Marc P Bonaca. Risk Profile of Comorbid Diabetes and Benefit of Rivaroxaban in Patients with Critical Limb Ischemia: Insights from VOYAGER PAD. American Diabetes Association 81st Scientific Sessions 2021 (virtual). Poster #2021-LB-6784-Diabetes. *Diabetes* (in press).
- 43) <u>Low Wang CC</u>, E. Sebastian Debus, Mark Nehler, Manesh Patel, Sonia Anand, Warren Capell, Eva Muehlhofer, Lloyd Haskell, Scott D Berkowitz, Rupert Bauersachs, Marc P Bonaca, on behalf of the VOYAGER PAD investigators. Risk Profile and the Efficacy and Safety of Rivaroxaban in Fragile PAD Patients after Revascularization: Insights from VOYAGER PAD. European Society of Cardiology Congress 2021: Latest Science in Special Populations.
- 44) Low Wang CC, E. Sebastian Debus, Mark Nehler, Manesh Patel, Sonia Anand, Matthew Jackson, Michael Szarek, Connie Hess, Warren Capell, Eva Muehlhofer, Lloyd Haskell, Scott D Berkowitz, Rupert Bauersachs, Marc P Bonaca, on behalf of the VOYAGER PAD investigators. Efficacy and Safety of Rivaroxaban in Patients with PAD with Concomitant Diabetes After Lower Extremity Revascularization. European Society of Cardiology Congress 2021: Latest Science in Special Populations.
- **45)** Griff M, Crawley S, Rowland A, Seggelke S, Hawkins RM, Grafals M, <u>Low Wang CC</u>. Diabetes management at the time of renal transplantation. American Diabetes Association's 82nd Scientific Sessions 2022. New Orleans, Louisiana. Poster 1293-P. Category 19: Transplantation.
- **46)** Seggelke SA, Griff M, Crawley S, Rowland A, Hawkins RM, <u>Low Wang CC</u>. Dysglycemia in patients without diabetes after renal transplantation. American Diabetes Association's 82nd Scientific Sessions 2022. New Orleans, Louisiana. Poster 928-P. Category 13-B Health Care Delivery—Quality Improvement.